Navigation Links
Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines

THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's executive vice president of Research & Development, has been elected a 2009 Fellow of the American Association for the Advancement of Science (AAAS). Each year the AAAS Council elects members whose "efforts on behalf of the advancement of science or its applications are scientifically or socially distinguished."

Perlmutter is being honored "for distinguished contributions leading to a more detailed understanding of signaling pathways controlling lymphocyte development and activation and to the discovery and development of novel biotherapeutics," according to AAAS.

Perlmutter joined Amgen as head of Research & Development in 2001 and over the past decade has led the company's effort to develop a robust pipeline that focuses on novel therapeutics to treat serious illnesses. With more than 50 molecules in development, the majority of which target pathways that have not previously been addressed in humans, Amgen's pipeline includes potential new treatments for cancer, asthma, diabetes, cardiovascular disease and many other life-threatening conditions.

Founded in 1848, AAAS is an international nonprofit professional association dedicated to advancing science, engineering and innovation around the world. AAAS publishes the peer-reviewed journal Science, as well as scientific newsletters, books and reports, and spearheads programs that raise the bar of understanding for science worldwide.

The complete list of 2009 Fellows appears in the Dec. 18 issue of Science.

About Roger M. Perlmutter

Dr. Perlmutter is Executive Vice President for Research and Development at Amgen. A graduate of Reed College (Portland, Oregon), Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University (St. Louis) in 1979. Thereafter he pursued clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco. From 1981 to 1984 he was a Lecturer in the Division of Biology at the California Institute of Technology. He joined the Departments of Medicine and Biochemistry and the Howard Hughes Medical Institute at the University of Washington (Seattle) in 1984, and in 1989 became Professor and founding Chairman of the Department of Immunology there. During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. In 1997 he left the University of Washington to join Merck and Co., ultimately rising to the rank of Executive Vice President, Worldwide Basic and Preclinical Research. He left Merck in 2001 to join Amgen in California. Dr. Perlmutter is also a director of Stem Cells, Inc., a Trustee of Reed College, and Chairman of the Board of Directors of the Institute for Systems Biology, a not-for-profit research institute based in Seattle, Washington. He was previously President of the American Association of Immunologists, and is a Fellow of the American Academy of Arts and Sciences.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit

    CONTACT: Amgen, Thousand Oaks
    Mary Klem: (805) 447-6979 (media)
    John Shutter: (805) 447-1060 (investors)



Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GRRL Tech Participant Offered Full Tuition Four-Year Scholarship to Roger Williams University
2. ALine, Inc. Expands Management, Adding Roger Anderson, Ph.D., as VP of Operations
4. Pharmasset Appoints Michael Rogers as Chief Development Officer
5. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
6. LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory
7. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
8. Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S.
9. Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
10. Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers
11. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
Breaking Biology Technology:
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
Breaking Biology News(10 mins):